# Evidence Summary
Mebendazole is one of the better-known **drug-repurposing candidates** in oncology because it combines broad mechanism coverage with a long-established non-cancer safety history.
### Research Overview
1. Broad preclinical evidence across ovarian, breast, colorectal, lung, medulloblastoma, glioma, and other cancers
2. Strong mechanistic support for anti-angiogenesis, mitotic disruption, apoptosis, and pathway inhibition
3. Early human clinical work suggests meaningful tolerability even at higher doses
4. Small studies suggest VEGF reduction and possible disease-modifying activity in selected cancers
5. Clinical evidence remains early and heterogeneous
### Clinical Application Status
**Approved status:** Approved as an anti-parasitic drug, not as an approved cancer drug.
**Clinical use:** Used experimentally in repurposing protocols and investigational integrative oncology settings.
**Evidence strength:** Strong preclinical evidence with emerging early clinical support, especially for safety and biomarker relevance.
### Key Advantages
1. **Multi-target action** — affects tubulin, angiogenesis, HIFs, Akt, NF-κB, and β-catenin-related survival pathways
2. **Repurposed-drug practicality** — long clinical history outside oncology and relatively familiar safety profile
3. **Angiogenesis inhibition** — especially through VEGFR2-related biology
4. **Unique ERK duality** — suppresses ERK in cancer cells while supporting anti-tumour immune signalling in immune cells
5. **CNS relevance** — meaningful interest in medulloblastoma and other brain-tumour contexts
### Key Considerations
1. **Human treatment data is still limited** — most evidence remains preclinical or early-stage clinical
2. **Dose translation matters** — anti-parasitic use and oncology-style use are not the same discussion
3. **Combination use requires care** — especially in patients on complex active-treatment regimens
4. **Interaction review is still essential** — even familiar drugs deserve oncology-specific review
5. **Sourcing and product strategy still need clearer practical guidance**
### Bottom line
Mebendazole is one of the most interesting repurposed-drug candidates in oncology. It should be understood as an investigational adjunct with a strong mechanism profile, not as a proven standalone cancer treatment.
### Key References
Mebendazole as a Candidate for Drug Repurposing in Oncology\
Emerging Perspectives on the Antiparasitic Mebendazole as a Cancer Therapy\
A phase 2a clinical study on the safety and efficacy of mebendazole in cancer\
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/evidence-summary.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.